On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Pharmacog. polym. & drug metab.
- (P. I) Psychopharmacology and pain
- Clinical pharmacogenomics
- Genetic variability of drug response
- Genetic variability in pharmacokin.
- Polymorphisms in drug metabolism
- Genetics-based dose adjustments
- Polymorphic drug metab. enzymes
- CYP2D6 - activity in Caucasians
- Variability in doxepin kinetics
- Antidep. drug treat. - problems
- CYP2D6 in antidep. drug treat.
- CYP2D6 polym. - antidep. drug treat.
- CYP2D6-based dose adjustments
- Genotype-based dose adjustments
- Genotype-phenotype interaction
- CYP2D6 interethnic differences
- Influence of polymorphisms in DME
- Types of adverse drug reactions
- Antidepressant drug treatment
- CYP2D6 geno. in ADR patients
- Adverse effect of antipsychotics
- CYP2D6 and haloperidol clearance
- Extrapyramidal sympt. & CYP2D6
- CYP2D6 - not just a DME
- CYP2D6 in psychiatry - summary
- PG polymorphisms in DME
- Codeine
- Morphine conc. after codeine treat.
- CYP2D6 sedat. after codeine treat.
- Tramadol
- PG polymorphisms in DME
- Metabolism of NSAIDs
- CYP2C genetic locus
- CYP2C9
- CYP2C9 - pharmacok. of ibuprofen
- CYP2C9 - prostaglandin E2
- CYP2C9 - COX-1 inhibition
- CYP2C9 - PK differences of NSAIDs
- Physiologic role of CYP2C8/9
- CYP inhibitors
- Conclusion (pain)
- Acknowledgments
Topics Covered
- Pharmacogenetic polymorphisms
- Biotransformation and clinical outcome
- Consequences of genotyping
- Feasibility for genotyping in antidepressant drug treatment
- Polymorphic cytochrome P450 enzyme CYP2D6
- Feasibility for genotyping in pain treatment
- CYP2C9, CYP2D6 and nonsteroidal analgetic drugs
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Stingl (formerly Kirchheiner), J. (2007, October 1). Clinical importance of pharmacogenetic polymorphisms affecting drug metabolism: psychopharmacology and pain [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/OUON8575.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Julia Stingl (formerly Kirchheiner) has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Clinical importance of pharmacogenetic polymorphisms affecting drug metabolism: psychopharmacology and pain
A selection of talks on Biochemistry
Hide